Registered title, quoted from ClinicalTrials.gov
A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
An open trial on stomach cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 3 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 3
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
- Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
- Study siteWest China Hospital四川大学华西医院ChengduHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07923214, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
5. For Ia monotherapy dose escalation: patients with cytologically and/or histopathologically confirmed advanced or metastatic solid tumors who have failed, are intolerant to, or have no effective standard treatment, or who refuse standard treatment
Inclusion criterion 5
8. Prior anticancer treatment-related toxicities resolved to ≤1 grade (except alopecia)
Inclusion criterion 8
4. Eastern Cooperative Oncology Group(ECOG) performance status 0-1
Inclusion criterion 4
7. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors, version 1.1(RECIST 1.1)
Inclusion criterion 7
4. Other active malignancies within 3 years before first dose (except curable tumors treated radically)
Exclusion criterion 4
10. Negative serum pregnancy test within 7 days before first dose
Inclusion criterion 10
11. Agreement to use effective contraception from ICF signing to ≥6 months after last dose
Inclusion criterion 11
12. No breastfeeding during study and ≥6 months after last dose
Inclusion criterion 12
13. Pregnant or lactating women
Exclusion criterion 13
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07923214, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 1. Voluntary signed informed consent and compliance with protocol requirements
- 2. Age ≥18 years, any gender
- 3. Life expectancy ≥12 weeks
- 4. Eastern Cooperative Oncology Group(ECOG) performance status 0-1
- 5. For Ia monotherapy dose escalation: patients with cytologically and/or histopathologically confirmed advanced or metastatic solid tumors who have failed, are intolerant to, or have no effective standard treatment, or who refuse standard treatment
- 6. Voluntary provision of tumor tissue specimens (archived within 2 years or fresh tissue)
- 7. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors, version 1.1(RECIST 1.1)
- 8. Prior anticancer treatment-related toxicities resolved to ≤1 grade (except alopecia)
- 9. Adequate organ and bone marrow function
- 10. Negative serum pregnancy test within 7 days before first dose
- 11. Agreement to use effective contraception from ICF signing to ≥6 months after last dose
- 12. No breastfeeding during study and ≥6 months after last dose
- 13. Understanding of study and voluntary written informed consent
Exclusion Criteria:
- 1. Anticancer therapy (chemotherapy, targeted therapy, biologics, immunotherapy, radiotherapy) within 4 weeks before first dose, or participation in other interventional clinical studies (observational studies excluded)
- 2. Strong Cytochrome P450 3A4(CYP3A4)inhibitors within 2 weeks before first dose
- 3. Strong Cytochrome P450 2C8(CYP2C8) inhibitors within 2 weeks before first dose
- 4. Other active malignancies within 3 years before first dose (except curable tumors treated radically)
- 5. Primary Central Nervous System(CNS) tumors or CNS metastases that failed local treatment (stable asymptomatic CNS metastases allowed)
- 6. Conditions affecting drug absorption or Pharmacokinetics(PK) parameters (e.g., uncontrolled nausea/vomiting, chronic diarrhea, malabsorption syndrome)
- 7. Uncontrolled or significant cardiovascular disease,
- 8. Active infection requiring systemic therapy within 2 weeks;
- 9. Major surgery within 4 weeks before first dose (except minor procedures)
- 10. Known allergy to study drug or excipients
- 11. Mental or cognitive impairment affecting study compliance
- 12. Known alcohol or drug dependence
- 13. Pregnant or lactating women
- 14. Investigator deems subject unsuitable for study participation
Quoted from ClinicalTrials.gov, NCT07923214, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07923214, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.